Haisco Pharmaceutical Group (SHE:002653) obtained the approval of China's medical products administrator to extend the use of ciprofolol injection for use in children and adolescents.
The anesthetic drug was initially approved for marketing in China in December 2020 for sedation and anesthesia for non-tracheal intubation surgery/procedures, general anesthesia induction and maintenance, and sedation during intensive care, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company slid 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments